P
Patrice Viens
Researcher at Aix-Marseille University
Publications - 378
Citations - 23071
Patrice Viens is an academic researcher from Aix-Marseille University. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 68, co-authored 370 publications receiving 21462 citations. Previous affiliations of Patrice Viens include University of the Mediterranean & French Institute of Health and Medical Research.
Papers
More filters
Journal ArticleDOI
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome.
Christophe Ginestier,Min Hee Hur,Emmanuelle Charafe-Jauffret,Florence Monville,Julie Dutcher,Marty Brown,Jocelyne Jacquemier,Patrice Viens,Celina G. Kleer,Suling Liu,Anne F. Schott,Daniel F. Hayes,Daniel Birnbaum,Max S. Wicha,Gabriela Dontu +14 more
TL;DR: It is shown that normal and cancer human mammary epithelial cells with increased aldehyde dehydrogenase activity (ALDH) have stem/progenitor properties and these cells contain the subpopulation of normal breast epithelium with the broadest lineage differentiation potential and greatest growth capacity in a xenotransplant model.
Journal ArticleDOI
Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature.
Emmanuelle Charafe-Jauffret,Christophe Ginestier,Flora Iovino,Julien Wicinski,Nathalie Cervera,Pascal Finetti,Min-Hee Hur,Mark E. Diebel,Florence Monville,Julie Dutcher,Marthy Brown,Patrice Viens,Luc Xerri,François Bertucci,Giorgio Stassi,Gabriela Dontu,Daniel Birnbaum,Max S. Wicha +17 more
TL;DR: It is shown that ALDEFLUOR-positive cells are responsible for mediating metastasis and the hierarchical organization of immortalized cell lines, establish techniques that can facilitate the characterization of regulatory pathways of CSCs, and identify potential stem cell markers and therapeutic targets.
Journal ArticleDOI
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses
David Cameron,Michelle Casey,Michael F. Press,Deborah Lindquist,Tadeusz Pienkowski,C. Gilles Romieu,Stephen Chan,Agnieszka Jagiełło-Gruszfeld,Bella Kaufman,John Crown,Arlene Chan,Mario Campone,Patrice Viens,Neville Davidson,Veira Gorbounova,Johannes Isaac Raats,Dimosthenis Skarlos,B. Newstat,Debasish F. Roychowdhury,Paolo Paoletti,Cristina Oliva,Stephen D. Rubin,S. Stein,Charles E. Geyer +23 more
TL;DR: The addition of lapatinib to capecitabine provides superior efficacy for women with HER2-positive, advanced breast cancer progressing after treatment with anthracycline-, taxane-, and trastuzumab-based therapy.
Journal ArticleDOI
Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer
Emmanuelle Charafe-Jauffret,Christophe Ginestier,Flora Iovino,Carole Tarpin,Mark E. Diebel,Benjamin Esterni,Gilles Houvenaeghel,Jean-Marc Extra,François Bertucci,François Bertucci,Jocelyne Jacquemier,Luc Xerri,Luc Xerri,Gabriela Dontu,Giorgio Stassi,Yi Xiao,Sanford H. Barsky,Daniel Birnbaum,Patrice Viens,Max S. Wicha +19 more
TL;DR: AlDH1 expression represents the first independent prognostic marker to predict metastasis and poor patient outcome in IBC and suggests that the metastatic, aggressive behavior of IBC may be mediated by a CSC component that displays ALDH enzymatic activity.
Journal ArticleDOI
Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial
Henri Roché,Pierre Fumoleau,Marc Spielmann,Jean-Luc Canon,Thierry Delozier,D. Serin,Michel Symann,Pierre Kerbrat,Patrick Soulié,Françoise Eichler,Patrice Viens,A. Monnier,A. Vindevoghel,Mario Campone,Marie-Josèphe Goudier,Jacques Bonneterre,Jean-Marc Ferrero,Anne-Laure Martin,Jean Genève,Bernard Asselain +19 more
TL;DR: The PACS 01 trial as mentioned in this paper compared six cycles of fluorouracil, epirubicin, and cyclophosphamide (FEC) with a sequential regimen of three cycles of FEC followed by three cycle of docetaxel as adjuvant treatment for node-positive early breast cancer.